期刊文献+

加替沙星片与左氧氟沙星片治疗急性细菌性感染疗效比较的meta分析 被引量:1

Meta-analysis of the efficacies on gatifloxacin tablets versus levofoxacin tablets in the treatment of acute bacterial infections
下载PDF
导出
摘要 目的比较加替沙星片与左氧氟沙星片治疗急性细菌性感染的疗效。方法应用m eta分析对有关加替沙星和左氧氟沙星治疗急性细菌性感染的临床疗效及细菌清除率进行定量综合分析,共入选10篇文献,可进行临床疗效评价病例992例,可进行细菌清除率比较病例1072例。结果同质性检验:细菌清除率比较,χ2=7.82,P=0.45;临床有效率比较,χ2=4.19,P=0.84;临床痊愈率比较,χ2=4.59,P=0.71;合并效应量的估计:细菌清除率比较,OR合并=0.98(0.63-1.53,Z=0.09,P=0.93);临床有效率比较,OR合并=1.29(0.80-2.10,Z=1.04,P=0.30);临床痊愈率比较,OR合并=1.21(0.89-1.63,Z=1.22,P=0.22)。结论国产加替沙星片与左氧氟沙星在治疗急性细菌性感染疾病的疗效相等。 Objective To compare the efficacies between gatifloxacin tablets and levofoxacin tablets in the treatment of acute bacterial infections. Methods The results of 10 random controlled trials in treating acute bacterial infections were analyzed by meta-analysis method. There were 992 cases analyzed to evaluate clinical efficacy and 1072 cases for bacterial clearance rate. Results The cited studies were homogeneous: in bacterial clearance rate analysis, with x^2=7.82 and P=0. 45; in clinical efficacy rates analysis, with x^2=4. 19 and P=0. 84 and in clinical cure rates analysis, with x^2=4.59 and P=0.71. Combined test showed, in bacterial clearance rate analysis, the combined OR=0.98 (0. 63-1.53, Z=0.09, P=0. 93); in clinical efficacy rate analysis, there was 1.29 (0.80-2.10, Z=1.04, P=0. 30), and in clinical cure rate analysis, there was 1.21 (0. 89- 1.63, Z = 1.22, P = 0.22). Conclusions The efficacies of domestic gatifloxacin tablets and levofoxacin tablets were equally effective in the treatment of acute bacterial respiratory and urinary tract infection.
机构地区 青岛市市立医院
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2007年第2期113-116,127,共5页 Chinese Journal of Antibiotics
关键词 加替沙星 左氧氟沙星 片剂 临床疗效 细菌感染 META分析 Gatifloxacin Levofoxacin Tablets Clinical efficacy Bacterial infections Metaanalysis
  • 相关文献

参考文献15

二级参考文献41

  • 1赵宁,俞顺章.Meta-analysis(元分析)I.Meta-analysis基本概念与内容[J].山西医学院学报,1995,26(3):203-205. 被引量:11
  • 2[1]Grasela DM. Clinical pharmacology of gatifloxacin, a new fluoroquinolone[J]. Clin Infect Dis, 2000, 31(Suppl 2): S51-58
  • 3[2]Perry CM, Ormrod D, Hurst M, et al. Gatifloxacin: a review of its use in the management of bacterial infections[J]. Drugs, 2002, 62: 169-207
  • 4[3]Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults[J]. Clin Infect Dis, 2000, 31: 347-382
  • 5[4]Niederman MS, Momdell CA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention[J]. Am J Respir Crit Care Med, 2001, 163: 1730-1754
  • 6[5]Pankuch GA, Jacobs MR, Appelbaum PC. Postantibiotic effects of gatifloxacin against Gram-positive and negative organisms[J]. Antimicrob Agents Chemother, 1999, 43: 2574-2575
  • 7[6]Sullivan JG, McElroy AD, Honsinger RW, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin[J]. J Respir Dis, 1999, 20(suppl): S49-S59
  • 8[7]Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone[J]. J Respir Dis, 1999, 20(suppl): s70-s75
  • 9[1]Saravolatz L, Manzor O, Check C, et al. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae[ J]. J Antimicrob Chemother, 2001 ;47:875-877.
  • 10[2]Huczko E, Conetta B, Bonner D, et al. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998[J]. Int J Antimicrob Agents, 2000; 16:401-405.

共引文献72

同被引文献13

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部